uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Linkoping Univ, Dept Med & Hlth Sci, SE-58185 Linkoping, Sweden..
Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden..
Linkoping Univ, Dept Med & Hlth Sci, SE-58185 Linkoping, Sweden..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Cancerfarmakologi och beräkningsmedicin. Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Experimentell och klinisk onkologi.
Vise andre og tillknytning
2015 (engelsk)Inngår i: Drug resistance updates, ISSN 1368-7646, E-ISSN 1532-2084, Vol. 21-22, s. 20-29Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival. The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target. However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting. Recently the deubiquitinases (DUBS), a diverse family of enzymes that catalyze ubiquitin removal, have attracted significant interest as targets for the development of next generation UPS inhibitors. In particular, pharmacological inhibition of the proteasomal cysteine DUBs (i.e., USP14 and UCHL5) has been shown to be particularly cytotoxic to cancer cells and inhibit tumour growth in several in vivo models. In the current review we focus on the modes of action of proteasome DUB inhibitors and discus the potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer.

sted, utgiver, år, opplag, sider
2015. Vol. 21-22, s. 20-29
Emneord [en]
Cancer therapeutics, Small molecule inhibitors, Proteasome, Deubiquitinase, DUB, alpha, beta-Unsaturated ketones, Apoptosis
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-266284DOI: 10.1016/j.drup.2015.06.001ISI: 000362060500003PubMedID: 26183292OAI: oai:DiVA.org:uu-266284DiVA, id: diva2:867780
Forskningsfinansiär
Swedish Cancer SocietySwedish Research CouncilSwedish Childhood Cancer FoundationTilgjengelig fra: 2015-11-06 Laget: 2015-11-06 Sist oppdatert: 2017-12-01bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Gullbo, Joachim

Søk i DiVA

Av forfatter/redaktør
Gullbo, Joachim
Av organisasjonen
I samme tidsskrift
Drug resistance updates

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 286 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf